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Summary
Background: The SF-6D is a new health state classiﬁcation and utility scoring system based on 6 dimensions (‘6D’)
of the Short Form 36, and permits a ‘‘bridging’’ transformation between SF-36 responses and utilities. The Health
Utilities Index, mark 3 (HUI3) is a valid and reliable multi-attribute health utility scale that is widely used. We
assessed within-subject agreement between SF-6D utilities and those from HUI3.
Methods: Patients at increased risk of sudden cardiac death and participating in a randomized trial of implantable
deﬁbrillator therapy completed both instruments at baseline. Score distributions were inspected by scatterplot and
histogram and mean score diﬀerences compared by paired t-test. Pearson correlation was computed between
instrument scores and also between dimension scores within instruments. Between-instrument agreement was by
intra-class correlation coeﬃcient (ICC).
Results: SF-6D and HUI3 forms were available from 246 patients. Mean scores for HUI3 and SF-6D were 0.61
(95% CI 0.60–0.63) and 0.58 (95% CI 0.54–0.62) respectively; a diﬀerence of 0.03 (p50.03). Score intervals for
HUI3 and SF-6D were (-0.21 to 1.0) and (0.30–0.95). Correlation between the instrument scores was 0.58 (95% CI
0.48–0.68) and agreement by ICC was 0.42 (95% CI 0.31–0.52). Correlations between dimensions of SF-6D were
higher than for HUI3.
Conclusions: Our study casts doubt on the whether utilities and QALYs estimated via SF-6D are comparable with
those from HUI3. Utility diﬀerences may be due to diﬀerences in underlying concepts of health being measured, or
diﬀerent measurement approaches, or both. No gold standard exists for utility measurement and the SF-6D is a
valuable addition that permits SF-36 data to be transformed into utilities to estimate QALYs. The challenge is
developing a better understanding as to why these classiﬁcation-based utility instruments diﬀer so markedly in their
distributions and point estimates of derived utilities. Copyright # 2003 John Wiley & Sons, Ltd.
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Introduction
The Short Form 36 (SF-36) health survey is a
standardized questionnaire used to assess health-
related quality of life (HRQL) across eight
dimensions of physical functioning, role limita-
tions (physical), bodily pain, general health,
vitality, social functioning, role limitations (emo-
tional) and mental health. Developed originally for
the Rand Medical Outcomes study, the SF-36 is
now one of the most widely used measures of
HRQL, with application to evaluation of speciﬁc
interventions and survey assessment of population
health over time and between groups [1]. The scale
limits of each dimension of SF-36 are 0 and 100
with higher scores indicating higher levels of
HRQL. Although there is a facility for an
aggregate SF-36 score across dimensions, this is
a simple arithmetic aggregation across the scales
and assigns them all equal weight in the total
score. This assumption limits the ability of SF-36
in making assessments of the net impact of an
intervention on HRQL. For example, assume
intervention A increases scores on the ﬁrst 4 of
the SF-36 dimensions and decreases scores on the
last 4 dimensions, with the opposite being ob-
served for intervention B. In this circumstance one
can only say that interventions A and B are
diﬀerent in their proﬁles of HRQL and not that
one is better or worse than the other.
Establishing the ‘net’ eﬀect of an intervention on
HRQL is particularly important in economic
evaluation where the goal is to compare the added
cost of a treatment to it’s added eﬀectiveness in
composite health units such quality-adjusted life-
years (QALYs) [2]. The QALY measure is a
quantitative framework for combining data on
survival and HRQL into a single metric; survival
time adjusted for HRQL using a utility scale with
anchors of full health (=1) to death (=0).
Based on principles of health state utility measure-
ment [3], utility scores can be measured
either directly, using preference trade-oﬀ exercises
such as standard gamble or time trade-oﬀ, or
indirectly using multi-attribute health status utility
classiﬁcation systems such as the Health Utilities
Index.
In our experience, many circumstances arise
where SF-36 data have been collected in a study
and researchers are interested to derive ‘Q’ weights
for quality-adjusted survival and estimating
QALYs. The question is whether it is feasible to
derive a valid and reliable method for creating a
‘bridge’ between a respondent’s eight dimensional
SF-36 score and a corresponding health state
utility weight in the interval 0-1.
There are two general approaches to the
empirical bridging between SF-36 and utility.
The ﬁrst is to use regression analysis on a dataset
where subjects have completed both SF-36 and a
utility measure. Nichol [4] used this method with
the Health Utilities Index (HUI) and Fryback [5]
with the Quality of Well Being Index (QWB); both
studies ﬁt linear additive models by ordinary
least squares with dimension scores of SF-36 as
independent variables explaining between 50 to
60% of the variance in utility score. The second
approach is to deﬁne and value a series of health
states using combinations of response levels (e.g. ‘a
little of the time’, ‘most of the time’) over SF-36
dimensions. This approach draws directly from the
conceptual and empirical logic of multi-attribute
utility theory (MAUT) [6] used in the construction
of HUI [7] and EQ5D [8] where an additive or
multiplicative utility function is estimated based
on a fractional factorial design from the universe
of all possible health states. The ‘bridge’ back to
SF-36 is formed via the beta coeﬃcients on the
utility scoring formula and the corresponding
levels on SF-36 dimensions.
This second approach has been adopted by
Brazier et al. who have reported both pilot work
[9] and a complete survey based on 836 respon-
dents in the UK [10] using an algorithm formed
from 6 dimensions of the SF-36 and referred to as
the SF-6D. In this study we assess the within-
subject agreement between the SF-6D utility
algorithm of Brazier et al. [10] and the HUI
(mark 3) using baseline assessments in patients at
high risk of sudden cardiac death who are
subjects in a randomized trial comparing drug
therapy with an implantable cardioverter deﬁbril-
lator (ICD).
The key pragmatic value of ‘bridging the gap’
between utility measures is that it enables the
comparison of studies that have been conducted
with either the SF-36 or HUI3. But it should be
stressed that our motivation is the study of
agreement between alternative utility measurement
scales and not the implied validation of the SF-6D
system on the presumption that the HUI3 is a gold
standard. Given that there is no criterion standard
for health state utility, the comparison of alter-
native instruments and their underlying stimuli
should improve our understanding of construct
validity in this ﬁeld.
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Methods
The SF-6D utility algorithm
The SF-6D algorithm is described in detail else-
where [9,10]. In brief, the algorithm is based on 6
of the 8 dimensions of SF-36 – ‘General Health’ is
omitted and ‘role limitation (physical)’ and ‘role
limitation (emotional)’ are combined. Each dimen-
sion has a number of levels such as ‘limited a lot’
and ‘limited a little’. The combination of levels
over dimensions deﬁnes a universe of 18 000
unique health states (=6 4 5 6 5 5). The
infeasibility of measuring utilities for all 18 000
states warrants a fractional factorial design and
therefore 249 health states were valued by 836
respondents from the UK general public. The
method of standard gamble was used to elicit
utility values using a two-stage ‘cascade’ [2]
technique: (1) a total of 6 states per subject were
valued relative to an upper anchor of no dysfunc-
tion (level 1 on all dimensions) and a lower anchor
of the lowest levels for all dimensions; (2) the lower
anchor was then valued against an upper anchor
of full health (level 1 on all dimensions) and a
lower anchor of death. The second lottery values
were then used to normalize the ﬁrst lottery values
on the conventional (0,1) scale of dead to full
health. Finally a linear additive utility model was
ﬁt by ordinary least squares and with SF-6D item-
levels and interactions as covariates. The model
preferred by the authors had an R2 of 0.53.
The DINAMIT trial dataset
The Deﬁbrillator in Acute Myocardial Infarction
Trial (DINAMIT) is a randomized, open label,
parallel group randomized trial of implantable
cardioverter deﬁbrillator (ICD) therapy versus usual
care in patients with recent myocardial infarction
and risk factors for sudden cardiac death. Details of
the study protocol are available elsewhere [11]. The
study will recruit 525 patients based on the
hypothesis that ICD therapy can reduce the annual
risk of all-cause mortality from 30% to 20%.
DINAMIT has sub-studies addressing both cost-
eﬀectiveness and quality of life. For the latter, and of
relevance to this study, patients complete both the
HUI and the SF-36 at baseline, 6 months and 1
year. Recruitment into DINAMIT is continuing,
and the present study is based on within-subject
comparison of the available sample (n ¼ 246) at
June 2000 who had completed baseline (pre-
randomization) assessments for HUI and SF-36.
Statistical methods
Data on classiﬁcation into HUI3 and SF-6D were
converted into utility scores based upon the
scoring algorithms from Feeny et al. [12] and
Brazier et al. [10] with imputation for missing item
values for SF-6D based on the guidance for SF-36
[13]. Descriptive statistics for the sample were
computed along with mean, standard deviation
and 95% conﬁdence intervals for utilities. The
within-subject diﬀerence in mean utility score was
tested by paired t-test. Utility data from the two
instruments were presented as a scatterplot.
Pearson correlation was computed and bivariate
linear regression was ﬁt by ordinary least squares.
A limitation of simple correlation and regression
is that two measures can be perfectly correlated
(i.e. fall on a straight line) but have poor
agreement, such that the straight line through the
X–Y scatterplot is not at 458 with a zero intercept.
For analysis of agreement we computed the intra-
class correlation coeﬃcient (ICC) by two-way
analysis of variance with factors of subject and
instrument. The ICC is equal to 1 only when
values lie on a 458 straight line through the origin
and there is perfect agreement within-subjects for
the two instruments. Finally, because indepen-
dence between utility attributes is an important
property of multi-attribute utility measures we
computed a correlation matrix between quality-of-
life dimensions for both HUI3 and SF-6D.
Results
A total of 310 patients had completed baseline
evaluation in the trial at the time of our study.
Patients had a mean (SD) age of 62.1 (11.2) years
and 26.4% were female. There were 239 SF-6D
and 263 HUI3 forms with no missing items. After
following the guidance for imputing missing item
values for SF-36 [13] and using the same rule for
HUI3, there were 267 SF-6D forms and 281 HUI3
forms eligible for analysis. Finally, the joint set of
patient forms with complete and imputed data for
both SF-6D and HUI3 was 246.
The distributions of utility scores by SF-6D and
HUI3 are presented in Figure 1. The mean utility
score for HUI3 was 0.61 (95% CI 0.60–0.63) and
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the mean score for SF-6D was 0.58 (95%CI 0.54–
0.62); the mean diﬀerence in score was 0.03
(p ¼ 0:03 by paired t-test). The SF-6D scores
passed the Kolmogorov-Smirnoﬀ test for normal-
ity at the 5% level but this was not true for HUI3
scores which show a skewed and bi-modal
distribution (Figure 1). The SF-6D had a mini-
mum value of 0.30 and a maximum value of 0.95;
this was a much smaller range than HUI3 which
had a minimum of 0.21 and a maximum of 1.00.
A scatterplot of SF-6D against HUI3 is
presented in Figure 2. Also plotted in Figure 2
are results from a bivariate regression indicating a
positive linear association between the two mea-
sures with an R2 goodness-of-ﬁt value of 0.34. This
corresponds to a Pearson Correlation Coeﬃcient
of 0.58 (95% CI 0.48–0.68). Also shown in Figure 2
is the 458 line of perfect agreement between the
two instruments. The intraclass correlation coeﬃ-
cient for agreement was 0.42 (95% 0.31–0.52).
Correlation matrices between dimensions of
functioning for both SF-6D and HUI3 are
presented in Table 1. All dimensions of SF-6D
have signiﬁcant (p50.05) positive correlation
ranging from 0.12 (mental vs physical) to 0.40
(vitality vs social). In contrast, for HUI3 of 28
correlations between dimensions only 14 are signiﬁcant (p50.05) and these range from 0.11
(hearing vs emotion) to 0.34 (ambulation vs
dexterity).
Discussion
Bridging the gap between health proﬁle measures
such as SF-36 and health state utilities for
construction of QALYs has obvious appeal. For
a resource-constrained researcher designing a
prospective evaluative study such as a clinical
trial, being able to use SF-36 to obtain both
health-related quality of life scores and health state
utilities for QALYs is clearly desirable. In this
study we assessed agreement between the new SF-
36-derived utility measure known as SF-6D and
HUI3, an established and widely used utility
measure.
Our results generally indicate poor agreement
between utilities derived by SF-6D and HUI3. The
intra-class correlation coeﬃcient was 0.42 and it is
clear from the scatterplot and regression line
(Figure 2) that the data do not cluster around
the 458 line of perfect agreement. The suggestion
from Figure 2 and related analysis is of systematic
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disagreement between SF-6D and HUI3; for
HUI3 values greater than 0.75, corresponding
SF-6D values are markedly lower and lie to the
left of the 458 line; for HUI3 values below 0.4
the corresponding SF-6D utility is markedly
higher.
The distributional diﬀerences between the SF-
6D and HUI3 are evident from the frequency
distributions in Figure 1. Data for HUI3 covers
the interval from 0.21 to 1.0 whereas the SF-6D
interval is only 0.30–0.95. The scatterplot shows a
much wider range of HUI3 values for any given
SF-6D value and the SF-6D distribution is normal
whereas the HUI3 distribution is not. Considera-
tion of scale extremes is also informative; for
example, 11 patients scored less than zero on
HUI3 (‘worse than death’) and on SF-6D these
same patients all scored 0.25 or greater. In
aggregate, the diﬀerence between measures in
mean score is 0.03 and statistically signiﬁcant at
the 5% level. Finally, we considered the important
principle of independence between utility dimen-
sions and showed that the correlations between
dimensions are greater for SF-6D than HUI3.
Three questions arise from this analysis; (1) are
the observed diﬀerences in mean utilities quantita-
tively ‘important’?; (2) can diﬀerences between the
utility scores be explained in terms of diﬀerences in
the instruments; (3) what are the implications of
these ﬁndings for prospective utility measurement
and further research?
The scoring basis of both HUI3 and SF-6D is
the standard gamble where strength of preference
for a health state is quantiﬁed in terms of the risk
of death a person would accept to avoid living in
the speciﬁed health state. For a utility score
diﬀerence of 0.03 not to be important, one would
have to be indiﬀerent about a 3% diﬀerence in
mortality risk. In a recent review by Drummond
[14] a diﬀerence of 0.03 is cited as being used in
sample size calculations as a minimally important
diﬀerence. Of note, Drummond also cites the same
minimal value of 0.03 as being used in other utility
systems such as EQ-5D. Furthermore, Samsa et al.
[15] reviewed the topic of minimally important
diﬀerences in health status measures and noted
that diﬀerences in HUI scores as small as 0.01 have
been considered to be important. Ultimately,
whether a diﬀerence of 0.03 is important will
depend upon the evaluative context.
Can diﬀerences in utility scores be explained by
diﬀerences in the SF-6D and HUI3 instruments?
Although the two instruments appear to be
measuring similar utility-based concepts of
strength-of-preference for health states, the con-
cept and characterization of health diﬀers between
the two measures. The HUI3 classiﬁcation is based
on a ‘within-the-skin’ deﬁnition of health that
Table 1. Correlation matrix (Kendall’s Tau) for Health Utilities Index and Short-Form 6D
Vision Hearing Speech Emotion Pain Ambulation Dexterity Cognition
(a) Health Utilities Index:
Vision 1.00
Hearing 0.09 1.00
Speech 0.04 0.07 1.00
Emotion 0.12a 0.11a 0.09 1.00
Pain 0.11a 0.02 0.03 0.24b 1.00
Ambulation 0.19b 0.02 0.01 0.21b 0.29b 1.00
Dexterity 0.09 0.08 0.10 0.27b 0.21b 0.34b 1.00
Cognition 0.09 0.08 0.08 0.18b 0.20b 0.27b 0.27b 1.00
Physical Role Social Pain Mental Vitality
(b) Short-Form 6D:
Physical 1.00
Role 0.19b 1.00
Social 0.24b 0.36b 1.00
Pain 0.26b 0.37b 0.39b 1.00
Mental 0.12a 0.19b 0.29b 0.24b 1.00
Vitality 0.24b 0.39b 0.40b 0.30b 0.17b 1.00
aCorrelation is signiﬁcant at the 0.05 level (2-tailed).
bCorrelation is signiﬁcant at the 0.01 level (2-tailed).
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focuses on impairments in vision, hearing, speech,
and cognition. The SF-36 is based on the broader
World Health Organization deﬁnition of health,
and addresses concerns with physical, mental and
social functioning. Therefore, the SF-6D measures
the impact of health on aspects of HRQOL such as
role and social functioning. Although the two
instruments do overlap in dimensions such as pain,
emotion or mental health, and ambulation or
physical functioning – there is no one-to-one
match on the dimensions of health being mea-
sured. The SF-36 also includes positive as well as
negative aspects of health and therefore the
deﬁnition of ‘full health’ is not the same between
the two measures.
There are several diﬀerences between the instru-
ments in how health states are valued. Valuation
of health states for both SF-6D and HUI3 were
done using the standard gamble technique in
diﬀerent ways. SF-6D health states were directly
valued by respondents using standard gamble; in
constrast, HUI3 states were directly valued by
respondents by visual analogue scale, with stan-
dard gamble scores being forecast by a statistical
power transformation. Furthermore, the utility-
theoretic framework for measurement is diﬀerent
for the two instruments. In developing HUI3,
Feeny et al. [12] reduced the health-state sampling
demands of their valuation task by invoking
simplifying assumptions from multi-attribute uti-
lity theory about the relationship between dimen-
sions. For example, the multiplicative form of
utility function, which is the basis of HUI3
scoring, permits a form of interaction between
dimensions that is assumed to be the same between
all dimensions and for all levels of each dimension.
In contrast, the SF-6D was valued using regression
techniques, with a linear additive model chosen on
the basis of goodness-of-ﬁt and parsimony. The
model estimates decrements for each movement
away from the highest level of functioning for each
dimension. It also contains an interaction term
which assumes the value of one when any
dimension in the health state is at the most severe
level, and zero otherwise.
What are the implications of our study for
future research? The ﬁrst issue is that any
comparison between HUI3 and SF-6D utilities
and QALYs should be made with caution. What
we cannot, as yet, determine from our data is the
extent to which the instrument comparability
problem still persists if one compares within-
instrument diﬀerences in utility scores. For
example, the diﬀerence in utility – over time or
between groups – may be the same for SF-6D and
HUI3 measured utilities, even though our study
suggests that the absolute utility scores will diﬀer.
If this were shown to be true then it would provide
some comfort for inter-study comparability of
QALYs. Subsequent data from our DINAMIT
trial will permit us to address this question,
because we will have repeated measures within
subjects and the randomization blinding will be
broken to permit comparison between treatment
groups. It would also be instructive, although
diﬃcult, to try to disentangle the competing
reasons as to why the instrument scores diﬀer; is
this due to the diﬀerent concepts of health being
measured or the extent to which they invoke the
assumptions of multi-attribute utility theory?
The challenge is that these multiple explanatory
factors are confounded in current datasets and
new experimental evidence would be costly to
generate.
There are several limitations to this study. First,
we have studied a single population with a speciﬁc
disease and the extent to which our observations
can be generalized is unclear. Second, we have
compared the new SF-6D utility algorithm only to
HUI3 – a comparison that arose by opportunity
not design. A broader study would be helpful,
comparing SF-6D with other multi-attribute sys-
tems such as EQ-5D and with direct measurement
of utility by standard gamble.
In conclusion, our study casts doubt on the
whether utilities and QALYs estimated via SF-6D
are comparable with those from HUI3. At this
stage it is not clear whether such diﬀerences arise
mainly from diﬀerences in underlying concepts of
health being measured or diﬀerent utility-theoretic
measurement approaches. There is no gold stan-
dard for health state utility measurement and the
SF-6D algorithm is a valuable addition that
permits SF-36 data to be transformed into utilities
to estimate QALYs. The challenge is developing a
better understanding as to why these classiﬁcation-
based utility instruments diﬀer so markedly in their
distributions and point estimates of derived
utilities.
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